LeonaBio, Inc. (LONA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -122.11M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 33.50M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-122.11M | (m) | (m) | $33.50M | (m) | (m) |
| 2026-03-31 | $-109.94M | (m) | (m) | $24.46M | (m) | (m) |
| 2025-12-31 | $-102.27M | (m) | (m) | $17.50M | (m) | (m) |
| 2025-09-30 | $-39.27M | (m) | (m) | $20.16M | (m) | (m) |
| 2025-06-30 | $-62.01M | (m) | (m) | $35.26M | (m) | (m) |
| 2025-03-31 | $-82.75M | (m) | (m) | $53.75M | (m) | (m) |
| 2024-12-31 | $-100.90M | (m) | (m) | $70.68M | (m) | (m) |
| 2024-09-30 | $-114.35M | (m) | (m) | $84.99M | (m) | (m) |
| 2024-06-30 | $-119.77M | (m) | (m) | $94.27M | (m) | (m) |
| 2024-03-31 | $-123.38M | (m) | (m) | $93.73M | (m) | (m) |
| 2023-12-31 | $-125.47M | (m) | (m) | $93.79M | (m) | (m) |
| 2023-09-30 | $-129.38M | (m) | (m) | $85.35M | (m) | (m) |
| 2023-06-30 | $-118.47M | (m) | (m) | $75.11M | (m) | (m) |
| 2023-03-31 | $-110.40M | (m) | (m) | $68.30M | (m) | (m) |
| 2022-12-31 | $-104.02M | (m) | (m) | $61.46M | (m) | (m) |
| 2022-09-30 | $-89.87M | (m) | (m) | $58.85M | (m) | (m) |
| 2022-06-30 | $-83.56M | (m) | (m) | $52.59M | (m) | (m) |
| 2022-03-31 | $-76.63M | (m) | (m) | $49.81M | (m) | (m) |
| 2021-12-31 | $-64.02M | (m) | (m) | $42.79M | (m) | (m) |
| 2021-09-30 | $-54.32M | (m) | (m) | $35.36M | (m) | (m) |
| 2021-06-30 | $-43.89M | (m) | (m) | $30.49M | (m) | (m) |
| 2021-03-31 | $-29.51M | (m) | (m) | $20.14M | (m) | (m) |
| 2020-12-31 | $-20.00M | (m) | (m) | $13.29M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-5.45M | (m) | (m) | $3.79M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |